JPH08103457A - Intraocular lens - Google Patents
Intraocular lensInfo
- Publication number
- JPH08103457A JPH08103457A JP26468694A JP26468694A JPH08103457A JP H08103457 A JPH08103457 A JP H08103457A JP 26468694 A JP26468694 A JP 26468694A JP 26468694 A JP26468694 A JP 26468694A JP H08103457 A JPH08103457 A JP H08103457A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- intraocular lens
- eye
- medicine
- optical part
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、水晶体を取り除いた後
に眼内に挿入される眼内レンズに関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an intraocular lens which is inserted into the eye after the lens is removed.
【０００２】[0002]
【従来の技術】白内障の治療としては、水晶体を摘出し
た後に眼内レンズを挿入する眼内レンズ手術がある。眼
内レンズ手術は近年急速に進歩し、その安全性が飛躍的
に向上し、手術の中でも最も安全な手術の部類に挙げら
れるほどになったといわれている。従来眼内レンズ手術
では、薬剤としては手術に直接必要な麻酔、ヒアルロン
酸ナトリウム、生理食塩水等を使用するにすぎなかっ
た。2. Description of the Related Art As a treatment for cataract, there is intraocular lens surgery in which an intraocular lens is inserted after the lens is removed. It has been said that intraocular lens surgery has made rapid progress in recent years, and the safety thereof has improved dramatically, and it has become one of the safest surgery categories among surgery. Conventionally, in intraocular lens surgery, anesthesia, sodium hyaluronate, physiological saline and the like, which are directly required for the surgery, have been used only as drugs.
【０００３】このように安全な手術として確立された眼
内レンズ手術においても、術後の炎症や後発白内障、と
いった水晶体を取り去ること自体に起因すると考えられ
る術後合併症がある。これら合併症の問題に対し、生体
内での適合性を向上させるべく眼内レンズの表面を処理
するという試みがある。また、合併症を抑制する薬剤も
開発されており、眼内レンズの表面にこれら薬剤を塗布
する試みもある。Even in the intraocular lens surgery established as a safe operation, there are postoperative complications such as postoperative inflammation and subsequent cataract which are considered to be caused by the removal of the lens itself. To address these complications, there have been attempts to treat the surface of the intraocular lens to improve its in vivo compatibility. In addition, drugs that suppress complications have been developed, and there are attempts to apply these drugs to the surface of the intraocular lens.
【０００４】[0004]
【発明が解決しようとする課題】しかしながら、眼内レ
ンズの表面処理による方法は、種々のものが提案されて
いるが、有効性、安定性、コストの点で満足できる物は
いまだ存在しない。また、眼内レンズへの薬剤の塗布も
予防や治療に要するほどの量を含むことはできない。し
かも、比較的長い時間その効果を保持することはできな
い。However, although various methods of surface treatment of an intraocular lens have been proposed, none of them are satisfactory in terms of effectiveness, stability and cost. Further, the application of the drug to the intraocular lens cannot include the amount required for prevention or treatment. Moreover, the effect cannot be maintained for a relatively long time.
【０００５】本発明は、上記のような事情に鑑み、眼内
レンズ手術において発生の予想される術後合併症の抑
制、さらには、術前からの内眼的疾患の治療のために薬
剤を効率よく投与できる眼内レンズを提供することを技
術課題とする。In view of the above circumstances, the present invention provides a drug for suppressing postoperative complications which are expected to occur in intraocular lens surgery, and for treating preoperative intraocular diseases. A technical problem is to provide an intraocular lens that can be efficiently administered.
【０００６】[0006]
【課題を解決するための手段】本発明は、上記課題を解
決するために、次のような構成を持つことを特徴とす
る。 （１） 水晶体を取り除いた後に眼内に挿入される眼内
レンズにおいて、液体の薬剤または液体に溶解した薬剤
を吸収もしくは保持するとともに、眼内に挿入後に吸収
もしくは保持した薬剤を徐々に眼内に放出する薬剤徐放
手段を設けたことを特徴とする。The present invention is characterized by having the following configuration in order to solve the above problems. (1) In an intraocular lens that is inserted into the eye after removing the crystalline lens, absorbs or holds a liquid drug or a drug dissolved in the liquid, and gradually absorbs the drug absorbed or held after insertion into the eye. It is characterized in that a drug sustained release means for releasing the drug is provided.
【０００７】（２） （１）の薬剤徐放手段の材質は含
水性又は含油性の材質からなり、液体の薬剤または液体
に溶解した薬剤を吸収含有することを特徴とする。(2) The material of the drug sustained release means of (1) is made of a water-containing or oil-containing material, and is characterized by absorbing and containing a liquid drug or a drug dissolved in the liquid.
【０００８】（３） （２）の眼内レンズは、屈折力を
持つ光学部と、該光学部を眼内に支持固定するための支
持部を有し、前記薬剤徐放手段は前記光学部または支持
部に取り付けたことを特徴とする。(3) The intraocular lens of (2) has an optical part having a refractive power and a support part for supporting and fixing the optical part in the eye, and the drug sustained-release means is the optical part. Alternatively, it is characterized in that it is attached to a supporting portion.
【０００９】（４） （２）の薬剤徐放手段は表面積を
増加させるための穴又は溝を備えることを特徴とする。(4) The drug sustained release means of (2) is characterized in that it has holes or grooves for increasing the surface area.
【００１０】（５） （１）の薬剤徐放手段は、液体の
薬剤または液体に溶解した薬剤を保持するとともに眼内
に挿入後に保持した薬剤を徐放するための多数の穴を持
つことを特徴とする。(5) The drug sustained-release means of (1) has a large number of holes for holding a liquid drug or a drug dissolved in a liquid and for slowly releasing the drug held after being inserted into the eye. Characterize.
【００１１】（６） （５）の薬剤徐放手段は、光学部
もしくは支持部に取り付け又は一体的に形成されること
を特徴とする。(6) The drug sustained release means of (5) is characterized in that it is attached to or integrally formed with the optical portion or the support portion.
【００１２】[0012]
【実施例１】以下、本発明の一実施例を図面に基づいて
説明する。図１は本発明に係る眼内レンズの平面形状を
示した図である。１は屈折力を持った光学部であり、一
般には凸レンズに形成される。２は光学部１を眼内に支
持固定するための支持部であり、支持部２は光学部１の
径方向に対向して周方向に湾曲して２本延び、支持部２
の弾性力により光学部１は眼内の所定位置に支持され
る。光学部１と支持部２は一体的に形成され、いわゆる
ワンピ−スタイプと称される眼内レンズである。その材
質はＰＭＭＡを主成分として、紫外線吸収剤等の色素を
分散させている。Embodiment 1 An embodiment of the present invention will be described below with reference to the drawings. FIG. 1 is a view showing a planar shape of an intraocular lens according to the present invention. Reference numeral 1 denotes an optical unit having a refractive power, which is generally formed as a convex lens. Reference numeral 2 is a support portion for supporting and fixing the optical portion 1 in the eye, and the support portion 2 is curved in the circumferential direction and extends two in opposition to the radial direction of the optical portion 1.
The optical part 1 is supported at a predetermined position in the eye by the elastic force of. The optical unit 1 and the support unit 2 are integrally formed and are an intraocular lens of a so-called one-piece type. The material is PMMA as a main component, and a pigment such as an ultraviolet absorber is dispersed therein.
【００１３】３は炎症や後発白内障などの術後合併症を
抑制する治療薬を含有させる薬剤含有部である。薬剤含
有部３は手術操作の障害とならないように、支持部２の
光学部側に取り付けられている。薬剤含有部３は含水性
又は含油性ポリマ−の材質（もちろん含水性でかつ含油
性の材質であっても差支えない）からなり、液体の薬剤
あるいは液体に溶解された薬剤を含有することができる
とともに、その薬剤を眼内で徐々に放出する機能（徐放
機能）を有している。この機能を有する材質としては、
ポリビニルピロリドン、ポリヒドロキシエチルメタクリ
レ−ト、ヂメチルホルムアミド、ポリビニルアルコ−
ル、ポリリン酸等に代表される材質が挙げられる。Reference numeral 3 is a drug-containing portion containing a therapeutic drug for suppressing postoperative complications such as inflammation and subsequent cataract. The drug-containing unit 3 is attached to the optical unit side of the support unit 2 so as not to hinder the surgical operation. The drug-containing portion 3 is made of a water-containing or oil-containing polymer material (of course, a water-containing and oil-containing material may be used), and can contain a liquid drug or a drug dissolved in a liquid. At the same time, it has a function of gradually releasing the drug in the eye (sustained release function). As a material having this function,
Polyvinylpyrrolidone, polyhydroxyethyl methacrylate, dimethylformamide, polyvinyl alcohol
Examples thereof include materials such as aluminum and polyphosphoric acid.
【００１４】薬剤含有部３の支持部２への取り付けは、
接着等周知の方法により物理的に取り付けることができ
る他、化学結合によっても行うことができる（両者の併
用であっても構わない）。なお、薬剤含有部は必要に応
じてその体積を変えることができる。薬剤含有部３への
薬剤の含有は、眼内レンズ挿入手術の直前に行うことも
できるが、眼内レンズの製造時に予め含ませておくこと
もできる。特に、溶液に溶解するタイプの薬剤において
は、予め含ませた後に溶媒のみを乾燥除去することで、
薬剤含有部３の分子マトリックスの中に長期にわたり薬
剤を保管させておくことができる。The attachment of the drug containing section 3 to the support section 2 is as follows.
In addition to being physically attached by a known method such as adhesion, it can also be performed by chemical bonding (both of them may be used in combination). The volume of the drug-containing part can be changed as necessary. The drug can be contained in the drug containing portion 3 immediately before the intraocular lens insertion operation, or can be contained in advance during the manufacture of the intraocular lens. In particular, in the case of the type of drug that dissolves in a solution, it is possible to remove only the solvent by drying after including it beforehand.
The drug can be stored in the molecular matrix of the drug-containing portion 3 for a long period of time.
【００１５】このような構成の眼内レンズは、薬剤含有
部３が薬剤のタンクあるいは担体といった役割を果たし
て眼内に薬剤を持ち込む。そして、眼内に挿入された薬
剤含有部３は、眼内で適当な期間にわたり薬剤を徐放す
るようになる。In the intraocular lens having such a structure, the drug-containing portion 3 serves as a tank or carrier for the drug and brings the drug into the eye. The drug-containing portion 3 inserted into the eye gradually releases the drug in the eye for an appropriate period.
【００１６】この薬剤含有部３による薬剤の徐放効果
を、本出願人は次のような実験を行い確認した。まず、
図２に示す如く中心部１０がＰＭＭＡ、周辺部１１がＰ
ＨＥＭＡからなるボタン状のものを作成する。作成方法
は、周知の技術によりＰＭＭＡのロッドを作成した後、
ＰＭＭＡロッド周囲をＰＨＥＭＡモノマ−で満たした
す。その後、重合開始剤を加え加熱し重合硬化させ、こ
れを機械加工により厚さ２ｍｍ程の寸法で切り出す。こ
のボタン状のものに染料を薬剤に見立て含有させた後、
所定量の水溶液中に浸し、その濃度を時間をおって測定
した。その結果、徐放効果は図３のグラフに示すように
１週間以上にわたることが確認できた。The applicant of the present invention confirmed the sustained release effect of the drug by the drug-containing portion 3 by conducting the following experiment. First,
As shown in FIG. 2, the central portion 10 is PMMA and the peripheral portion 11 is P
A button-shaped object made of HEMA is created. As for the method of making, after making a rod of PMMA by a well-known technique,
Fill around the PMMA rod with PHEMA monomer. After that, a polymerization initiator is added and heated to polymerize and harden, and this is cut out by machining to have a thickness of about 2 mm. After adding the dye to this button-like substance as a drug,
It was immersed in a predetermined amount of aqueous solution, and its concentration was measured over time. As a result, it was confirmed that the sustained release effect lasted for 1 week or longer as shown in the graph of FIG.
【００１７】なお、上記の実施例では、薬剤含有部３を
支持部２へ取り付けた例を示したが、薬剤含有部３の取
り付けは、手術操作の障害や光学的性能に影響を与えな
い位置が好ましく、例えば図４に示す位置等種々の部分
に取り付けることができる（図中の斜線で示す部分が薬
剤含有部である）。図４の（ａ）は光学部１の周回りに
取り付けた例、（ｂ）は支持部２自体を薬剤含有部とし
た例、（ｃ）は光学部１の裏面（または表面）に取り付
けた例である。（ｄ）は光学部１と支持部２とを別個に
加工した後、これをカシメ等により接合したいわゆるス
リ−ピ−スタイプの眼内レンズへの取り付け例であり、
薬剤含有部は円板状の部分からのびた足がカシメ等によ
り光学部１に取り付けられている。（ｅ）のものは薬剤
含有部に穴を設けた例であり、この場合、薬剤含有部の
表面積を増加させることができるので、薬剤の吸収、徐
放の速度を制御することも可能となる。また穴を設ける
代わりに溝を設けるようにしてもよい。In the above embodiment, the drug-containing portion 3 is attached to the support portion 2. However, the attachment of the drug-containing portion 3 does not affect the operation or the optical performance. However, it can be attached to various portions such as the position shown in FIG. 4 (the shaded portion in the drawing is the drug-containing portion). 4A shows an example in which the optical unit 1 is attached around the circumference, FIG. 4B shows an example in which the supporting unit 2 itself is a drug-containing unit, and FIG. 4C shows an example in which it is attached to the back surface (or front surface) of the optical unit 1. Here is an example. (D) is an example of attachment to a so-called sleep-piece type intraocular lens in which the optical part 1 and the support part 2 are separately processed and then joined by caulking,
The drug-containing part has legs extending from a disk-shaped part attached to the optical part 1 by caulking or the like. The case of (e) is an example in which a hole is provided in the drug-containing part. In this case, since the surface area of the drug-containing part can be increased, it is also possible to control the rate of drug absorption and sustained release. . Further, a groove may be provided instead of the hole.
【００１８】なお、薬剤含有部３に含有させる薬剤は、
一つに限られるわけではなく、複数であっても良い。複
数の薬剤を含有させる場合は、薬剤含有部３を複数設け
ることにより別々に含有させることもできる。The medicine contained in the medicine containing section 3 is
The number is not limited to one and may be plural. When a plurality of medicines are contained, they can be contained separately by providing a plurality of medicine containing parts 3.
【００１９】[0019]
【実施例２】図５は実施例２の眼内レンズの平面形状を
示した図である。３´は多数の穴３´ａを持った薬剤保
持部であり、薬剤保持部３´は支持部２´及び光学部１
´とともに一体的に形成されたものである。材質はＰＭ
ＭＡ等周知のものが使用でき、表面処理が施されたもの
であってもよい。[Embodiment 2] FIG. 5 is a view showing a planar shape of an intraocular lens according to Embodiment 2. Reference numeral 3'denotes a medicine holding portion having a large number of holes 3'a, and the medicine holding portion 3'is a support portion 2'and an optical portion
It is integrally formed with the ‘ Material is PM
Well-known materials such as MA can be used and may be surface-treated.
【００２０】実施例２の眼内レンズにおいては、薬剤保
持部３´に開けられた多数の穴３´ａに薬剤あるいは薬
剤溶液を染み込ませることにより、この多数の穴が薬剤
を眼内に持ち込む担体の役目を果たす。薬剤を薬剤保持
部３´の穴３´ａに含有させるのは、実施例１と同様に
眼内レンズ挿入手術直前に行ってもよいし、製造時に予
め含ませておくこともできる。溶液に溶解するタイプの
薬剤の場合は、予め含ませた後溶媒のみ乾燥除去するこ
とで、結晶、あるいは紛体の状態で穴に保持され、長期
にわたり容易に薬剤を保管できる。さらにこの状態にす
ると、溶解した後に薬剤としての機能を果たすまでの時
間が溶液の状態のときより長くかかるため、長期間の徐
放効果が期待できる（徐放効果が早く必要な場合は、挿
入前に溶液に戻して行っても良い）。In the intraocular lens of the second embodiment, a large number of holes 3'a formed in the medicine holding portion 3'are impregnated with the medicine or the medicine solution, so that the large number of holes bring the medicine into the eye. Serves as a carrier. The drug may be contained in the hole 3′a of the drug holding portion 3 ′ just before the intraocular lens insertion operation as in the first embodiment, or may be contained in advance at the time of manufacturing. In the case of a drug of a type that dissolves in a solution, by preliminarily containing it and then only removing the solvent by drying, the drug is retained in the holes in the form of crystals or powder, and the drug can be easily stored for a long period of time. Furthermore, in this state, the time it takes to function as a drug after dissolution is longer than that in the solution state, so a long-term sustained release effect can be expected (if the sustained release effect is early, It may be returned to the solution before).
【００２１】薬剤保持部３´による薬剤の保持能力を、
本出願人は次のような実験を行い確認した。図６に示す
ごとく、ＰＭＭＡのロッドを周知の技術により旋盤加工
し、中心部２０を光学部としてその周辺部２１にドリル
により０．３ｍｍの穴２２を多数開ける。その後、研磨
を施す。これに濃度３０％の塩化ナトリウム水溶液を薬
剤に見立て穴２２に染み込ませた後、溶媒である水を蒸
発乾燥させて穴の中に塩化ナトリウムの結晶を保持させ
た。この結果、アサンプル穴内に０．６８ｇの塩化ナト
リウムを保持していた。The drug holding capacity of the drug holding unit 3'is
The applicant confirmed the following experiments. As shown in FIG. 6, a PMMA rod is lathe-machined by a well-known technique, and a large number of 0.3 mm holes 22 are drilled in the peripheral portion 21 with the central portion 20 as an optical portion. After that, polishing is performed. After a sodium chloride aqueous solution having a concentration of 30% was impregnated into this as a drug and the holes 22 were soaked, water as a solvent was evaporated and dried to retain sodium chloride crystals in the holes. As a result, 0.68 g of sodium chloride was held in the sample hole.
【００２２】実施例２の眼内レンズにおいても、実施例
１と同様に薬剤保持部３´を設ける位置は種々の位置に
設けることが可能である（図７参照）。また、薬剤保持
部３´の体積及び穴３´ａの大きさも必要に応じて変え
ることができる。Also in the intraocular lens of the second embodiment, the drug holding portion 3'can be provided at various positions as in the first embodiment (see FIG. 7). Further, the volume of the medicine holding portion 3'and the size of the hole 3'a can be changed as required.
【００２３】[0023]
【発明の効果】以上説明したように、本発明の眼内レン
ズによれば、眼内レンズ手術における術後合併症の抑制
や術前からの内眼的疾患の治療のために必要な薬剤を眼
内レンズに十分に付与できるため、薬剤の投与を効率良
く行うことができる。これにより、さらに高い手術の安
全性と質の高い視機能供与への寄与が可能となる。As described above, according to the intraocular lens of the present invention, a drug necessary for suppressing postoperative complications in intraocular lens surgery and treating preoperative intraocular diseases is provided. Since it can be sufficiently applied to the intraocular lens, the drug can be efficiently administered. This makes it possible to contribute to higher surgical safety and provision of high-quality visual function.
【図面の簡単な説明】[Brief description of drawings]
【図１】実施例１の眼内レンズの平面形状を示す図であ
る。FIG. 1 is a diagram showing a planar shape of an intraocular lens of Example 1.
【図２】薬剤の徐放効果を確認するために行った実験の
テストサンプルを示す図である。FIG. 2 is a diagram showing a test sample of an experiment conducted for confirming the sustained release effect of a drug.
【図３】図２のテストサンプルの徐放効果を示す図であ
る。FIG. 3 is a diagram showing a sustained release effect of the test sample of FIG.
【図４】実施例１における薬剤含有部３の他の取り付け
位置の例を示した図である。FIG. 4 is a diagram showing an example of another attachment position of the medicine containing part 3 in the first embodiment.
【図５】実施例２の眼内レンズの平面形状を示した図で
ある。FIG. 5 is a diagram showing a planar shape of an intraocular lens of Example 2.
【図６】薬剤保持部３´による薬剤の保持能力を確認す
るために行った実験のテストサンプルを示す図である。FIG. 6 is a diagram showing a test sample of an experiment conducted for confirming the drug holding ability of the drug holding unit 3 ′.
【図７】薬剤保持部３´を設ける位置の他の例を示した
図である。FIG. 7 is a diagram showing another example of the position where the drug holding unit 3 ′ is provided.
１ 光学部 ２ 支持部 ３ 薬剤含有部 ３´ 薬剤保持部 ３´ａ 穴 1 Optical part 2 Support part 3 Drug containing part 3'Drug holding part 3'a hole
─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成７年６月３０日[Submission date] June 30, 1995
【手続補正１】[Procedure Amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】請求項１[Name of item to be corrected] Claim 1
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【手続補正２】[Procedure Amendment 2]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００６[Correction target item name] 0006
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【０００６】[0006]
【課題を解決するための手段】本発明は、上記課題を解
決するために、次のような構成を持つことを特徴とす
る。 （１） 水晶体を取り除いた後に眼内に挿入される眼内
レンズにおいて、薬剤を吸収もしくは保持するととも
に、眼内に挿入後に吸収もしくは保持した薬剤を徐々に
眼内に放出する薬剤除放手段を設けたことを特徴とす
る。The present invention is characterized by having the following configuration in order to solve the above problems. (1) In an intraocular lens that is inserted into the eye after removing the crystalline lens, a drug releasing means that absorbs or holds the drug and gradually releases the drug absorbed or held after insertion into the eye into the eye. It is characterized by being provided.
Claims (6)
る眼内レンズにおいて、液体の薬剤または液体に溶解し
た薬剤を吸収もしくは保持するとともに、眼内に挿入後
に吸収もしくは保持した薬剤を徐々に眼内に放出する薬
剤徐放手段を設けたことを特徴とする眼内レンズ。1. An intraocular lens that is inserted into the eye after removing the lens, absorbs or retains a liquid drug or a drug dissolved in the liquid, and gradually absorbs the drug absorbed or retained after being inserted into the eye. An intraocular lens comprising a drug sustained release means for releasing the drug into the eye.
又は含油性の材質からなり、液体の薬剤または液体に溶
解した薬剤を吸収含有することを特徴とする眼内レン
ズ。2. An intraocular lens characterized in that the material for the drug sustained-release means according to claim 1 is made of a water-containing or oil-containing material and absorbs and contains a liquid drug or a drug dissolved in the liquid.
光学部と、該光学部を眼内に支持固定するための支持部
を有し、前記薬剤徐放手段は前記光学部または支持部に
取り付けたことを特徴とする眼内レンズ。3. The intraocular lens according to claim 2 has an optical section having a refractive power and a support section for supporting and fixing the optical section in the eye, and the drug sustained-release means is the optical section or An intraocular lens characterized by being attached to a support portion.
させるための穴又は溝を備えることを特徴とする眼内レ
ンズ。4. The intraocular lens according to claim 2, wherein the drug sustained-release means comprises holes or grooves for increasing the surface area.
または液体に溶解した薬剤を保持するとともに眼内に挿
入後に保持した薬剤を徐放するための多数の穴を持つこ
とを特徴とする眼内レンズ。5. The drug sustained-release means according to claim 1, characterized in that it holds a liquid drug or a drug dissolved in the liquid and has a large number of holes for sustained-release of the drug held after being inserted into the eye. And an intraocular lens.
くは支持部に取り付け又は一体的に形成されることを特
徴とする眼内レンズ。6. The intraocular lens according to claim 5, wherein the drug sustained-release means is attached to or integrally formed with the optical part or the support part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26468694A JP3640690B2 (en) | 1994-10-03 | 1994-10-03 | Intraocular lens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26468694A JP3640690B2 (en) | 1994-10-03 | 1994-10-03 | Intraocular lens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08103457A true JPH08103457A (en) | 1996-04-23 |
| JP3640690B2 JP3640690B2 (en) | 2005-04-20 |
Family
ID=17406794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP26468694A Expired - Fee Related JP3640690B2 (en) | 1994-10-03 | 1994-10-03 | Intraocular lens |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3640690B2 (en) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000030566A1 (en) * | 1998-11-20 | 2000-06-02 | Staar Surgical Company, Inc. | Posterior chamber intraocular implant device, and packaging therefor |
| JP2005523049A (en) * | 2002-01-31 | 2005-08-04 | シメッド ライフ システムズ インコーポレイテッド | Medical device for releasing biologically active substances |
| US20060271177A1 (en) * | 2003-05-28 | 2006-11-30 | Christie Bruce A | Mask configured to maintain nutrient transport without producing visible diffraction patterns |
| WO2007112946A1 (en) * | 2006-03-30 | 2007-10-11 | Universite De Geneve | Intraocular lens with drug delivery system attached thereto |
| US20110040378A1 (en) * | 2007-01-29 | 2011-02-17 | Werblin Research & Development Corp. | Intraocular lens system |
| JP2014090772A (en) * | 2012-11-01 | 2014-05-19 | Chukyo Medical Co Inc | Intraocular implant, intraocular implant set, and intraocular lens |
| US9005281B2 (en) | 2009-08-13 | 2015-04-14 | Acufocus, Inc. | Masked intraocular implants and lenses |
| US9204962B2 (en) | 2013-03-13 | 2015-12-08 | Acufocus, Inc. | In situ adjustable optical mask |
| US9326845B2 (en) | 2014-04-24 | 2016-05-03 | Chukyo Medical Co., Inc. | Intraocular implant, intraocular implant set and intraocular lens |
| US9427311B2 (en) | 2009-08-13 | 2016-08-30 | Acufocus, Inc. | Corneal inlay with nutrient transport structures |
| US9427922B2 (en) | 2013-03-14 | 2016-08-30 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| US9545303B2 (en) | 2011-12-02 | 2017-01-17 | Acufocus, Inc. | Ocular mask having selective spectral transmission |
| US9943403B2 (en) | 2014-11-19 | 2018-04-17 | Acufocus, Inc. | Fracturable mask for treating presbyopia |
| US10004593B2 (en) | 2009-08-13 | 2018-06-26 | Acufocus, Inc. | Intraocular lens with elastic mask |
| US10687935B2 (en) | 2015-10-05 | 2020-06-23 | Acufocus, Inc. | Methods of molding intraocular lenses |
| EP3826589A4 (en) * | 2018-07-23 | 2022-04-20 | The Regents of the University of Colorado, a body corporate | Ophthalmic device for drug delivery |
| US11364110B2 (en) | 2018-05-09 | 2022-06-21 | Acufocus, Inc. | Intraocular implant with removable optic |
| US11464625B2 (en) | 2015-11-24 | 2022-10-11 | Acufocus, Inc. | Toric small aperture intraocular lens with extended depth of focus |
-
1994
- 1994-10-03 JP JP26468694A patent/JP3640690B2/en not_active Expired - Fee Related
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000030566A1 (en) * | 1998-11-20 | 2000-06-02 | Staar Surgical Company, Inc. | Posterior chamber intraocular implant device, and packaging therefor |
| JP2005523049A (en) * | 2002-01-31 | 2005-08-04 | シメッド ライフ システムズ インコーポレイテッド | Medical device for releasing biologically active substances |
| US8858624B2 (en) | 2003-05-28 | 2014-10-14 | Acufocus, Inc. | Method for increasing the depth of focus of a patient |
| US10869752B2 (en) | 2003-05-28 | 2020-12-22 | Acufocus, Inc. | Mask for increasing depth of focus |
| US20060271177A1 (en) * | 2003-05-28 | 2006-11-30 | Christie Bruce A | Mask configured to maintain nutrient transport without producing visible diffraction patterns |
| US9138142B2 (en) * | 2003-05-28 | 2015-09-22 | Acufocus, Inc. | Masked intraocular devices |
| WO2007112946A1 (en) * | 2006-03-30 | 2007-10-11 | Universite De Geneve | Intraocular lens with drug delivery system attached thereto |
| US9398949B2 (en) * | 2007-01-29 | 2016-07-26 | Emmetropia, Inc. | Intraocular lens system |
| US20110040378A1 (en) * | 2007-01-29 | 2011-02-17 | Werblin Research & Development Corp. | Intraocular lens system |
| US10004593B2 (en) | 2009-08-13 | 2018-06-26 | Acufocus, Inc. | Intraocular lens with elastic mask |
| US9492272B2 (en) | 2009-08-13 | 2016-11-15 | Acufocus, Inc. | Masked intraocular implants and lenses |
| US11311371B2 (en) | 2009-08-13 | 2022-04-26 | Acufocus, Inc. | Intraocular lens with elastic mask |
| US9427311B2 (en) | 2009-08-13 | 2016-08-30 | Acufocus, Inc. | Corneal inlay with nutrient transport structures |
| US11357617B2 (en) | 2009-08-13 | 2022-06-14 | Acufocus, Inc. | Method of implanting and forming masked intraocular implants and lenses |
| US9005281B2 (en) | 2009-08-13 | 2015-04-14 | Acufocus, Inc. | Masked intraocular implants and lenses |
| US10548717B2 (en) | 2009-08-13 | 2020-02-04 | Acufocus, Inc. | Intraocular lens with elastic mask |
| US10449036B2 (en) | 2009-08-13 | 2019-10-22 | Acufocus, Inc. | Masked intraocular implants and lenses |
| US9545303B2 (en) | 2011-12-02 | 2017-01-17 | Acufocus, Inc. | Ocular mask having selective spectral transmission |
| US9848979B2 (en) | 2011-12-02 | 2017-12-26 | Acufocus, Inc. | Ocular mask having selective spectral transmission |
| US10342656B2 (en) | 2011-12-02 | 2019-07-09 | Acufocus, Inc. | Ocular mask having selective spectral transmission |
| US10765508B2 (en) | 2011-12-02 | 2020-09-08 | AcFocus, Inc. | Ocular mask having selective spectral transmission |
| JP2014090772A (en) * | 2012-11-01 | 2014-05-19 | Chukyo Medical Co Inc | Intraocular implant, intraocular implant set, and intraocular lens |
| US9603704B2 (en) | 2013-03-13 | 2017-03-28 | Acufocus, Inc. | In situ adjustable optical mask |
| US10939995B2 (en) | 2013-03-13 | 2021-03-09 | Acufocus, Inc. | In situ adjustable optical mask |
| US11771552B2 (en) | 2013-03-13 | 2023-10-03 | Acufocus, Inc. | In situ adjustable optical mask |
| US10350058B2 (en) | 2013-03-13 | 2019-07-16 | Acufocus, Inc. | In situ adjustable optical mask |
| US9204962B2 (en) | 2013-03-13 | 2015-12-08 | Acufocus, Inc. | In situ adjustable optical mask |
| US9844919B2 (en) | 2013-03-14 | 2017-12-19 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| US10583619B2 (en) | 2013-03-14 | 2020-03-10 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| US10183453B2 (en) | 2013-03-14 | 2019-01-22 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| US9573328B2 (en) | 2013-03-14 | 2017-02-21 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| US9427922B2 (en) | 2013-03-14 | 2016-08-30 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
| US9326845B2 (en) | 2014-04-24 | 2016-05-03 | Chukyo Medical Co., Inc. | Intraocular implant, intraocular implant set and intraocular lens |
| US9943403B2 (en) | 2014-11-19 | 2018-04-17 | Acufocus, Inc. | Fracturable mask for treating presbyopia |
| US10687935B2 (en) | 2015-10-05 | 2020-06-23 | Acufocus, Inc. | Methods of molding intraocular lenses |
| US11690707B2 (en) | 2015-10-05 | 2023-07-04 | Acufocus, Inc. | Methods of molding intraocular lenses |
| US11464625B2 (en) | 2015-11-24 | 2022-10-11 | Acufocus, Inc. | Toric small aperture intraocular lens with extended depth of focus |
| US11364110B2 (en) | 2018-05-09 | 2022-06-21 | Acufocus, Inc. | Intraocular implant with removable optic |
| EP3826589A4 (en) * | 2018-07-23 | 2022-04-20 | The Regents of the University of Colorado, a body corporate | Ophthalmic device for drug delivery |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3640690B2 (en) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH08103457A (en) | Intraocular lens | |
| US10617559B2 (en) | High-precision drug delivery by dual-domain ocular device | |
| JP5530371B2 (en) | Ring-shaped device | |
| Gurtler et al. | Patent literature review of ophthalmic inserts | |
| JP5954888B2 (en) | Ophthalmic device capable of delivering therapeutic agents and uses thereof | |
| JPH04292609A (en) | Copolymer and intraocular implant prepared from the copolymer | |
| US10383721B2 (en) | Photochemically induced engagement of intraocular implants | |
| ES2856886T3 (en) | Intraocular lens comprising drug-containing microspheres | |
| JP2002511012A (en) | Method for preparing foldable high refractive index acrylic ophthalmic device material | |
| JP2012511395A (en) | Contact lens drug delivery device | |
| EP1318778A4 (en) | Treatment for high pressure bleeding | |
| US20100310622A1 (en) | Dry eye treatment by puncta plugs | |
| US6887269B1 (en) | Ophthalmologic implant | |
| JPWO2019188663A1 (en) | Embolic material and its manufacturing method | |
| WO2017053733A1 (en) | Biodegradable microsphere-hydrogel ocular drug delivery system | |
| EP0954341B1 (en) | Intraocular lens containing releasable medication | |
| US11160908B2 (en) | Intraocular drug delivery and filter device and methods of using same | |
| CN211156651U (en) | Amnion invisible contact lens | |
| JP5238115B2 (en) | Drug sustained-release polymer gel and ophthalmic lens comprising the same | |
| JP7408153B2 (en) | antimicrobial contact lenses | |
| WO2023183372A2 (en) | Therapeutic composition delivery device | |
| JP2003301014A (en) | Ionic ocular lens and ocular lens having drug-sustained releasing property using it | |
| RU2557925C1 (en) | Biodegradable multilayer implant for administering drug substances into vitreal cavity of eye | |
| JPWO2021092470A5 (en) | ||
| WO2002060486A2 (en) | Controlled release microsphere system for administration of drug to the eye |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Effective date: 20040413 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040728 |
|
| A521 | Written amendment |
Effective date: 20040921 Free format text: JAPANESE INTERMEDIATE CODE: A523 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Effective date: 20050119 Free format text: JAPANESE INTERMEDIATE CODE: A61 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 3 Free format text: PAYMENT UNTIL: 20080128 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 4 Free format text: PAYMENT UNTIL: 20090128 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090128 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 5 Free format text: PAYMENT UNTIL: 20100128 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 6 Free format text: PAYMENT UNTIL: 20110128 |
|
| LAPS | Cancellation because of no payment of annual fees |